Sign in
4

Changes in Ownership

Summit Therapeutics Inc. Filed Acc 0000921895-20-002948

Options or other derivatives

  • Director acquired 203,323 shares (grant or award)

From the SEC's structured data for this filing

Trades in this filing

Insider Date Transaction Shares Price Value Owned after D/I In the form
Derivatives
Zanganeh Maky Director 2020-11-11 Grant or award · Stock Option (right to buy) +200,000 1,321,177 D
Zanganeh Maky Director 2020-11-11 Grant or award · Stock Option (right to buy) +3,323 1,324,500 D
Loading xslF345X03/form412566001_11132020.xml…